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Background: Although human torque teno viruses (TTVs) were first discovered in 1997, still many associated aspects are
not clarified yet. The viruses reveal a remarkable heterogeneity and it is possible that some genotypes are more pathogenic
than others. The identification of all genotypes is essential to confirm previous pathogenicity data, and an unbiased search
for novel viruses is needed to identify TTVs that might be related to disease.
Method: The virus discovery technique VIDISCA-454 was used to screen serum of 55 HIV-1 positive injecting drug users,
from the Amsterdam Cohort Studies, in search for novel blood-blood transmittable viruses which are
undetectable via normal diagnostics or panvirus-primer PCRs.
Results: A novel torque teno mini virus (TTMV) was identified in two patients and the sequence of the full genomes were
determined. The virus is significantly different from the known TTMVs (< 40% amino acid identity in ORF1), yet it contains
conserved characteristics that are also present in other TTMVs. The virus is chronically present in both patients, and these
patients both suffered from a pneumococcal pneumonia during follow up and had extremely low B-cells counts.
Conclusion: We describe a novel TTMV which we tentatively named TTMV-13. Further research is needed to
address the epidemiology and pathogenicity of this novel virus.
Keywords: Torque teno mini virus, VIDISCA-454, Virus discoveryBackground
Human torque teno virus (TTV) was first discovered in a
Japanese patient with acute post-transfusion hepatitis in
1997 [1]. It is a small and non-enveloped virus, with the
size of 30 nm diameter, which carries an approximately
3.8 kb, circular negative sense, single-stranded DNA gen-
ome [2,3]. According to the latest International Commit-
tee on Taxonomy of Viruses (ICTV) classification [4,5],
TTV has been classified into the Anelloviridae family
which includes also torque teno mini virus (TTMV),
formerly known as TTV-like Mini virus (TLMV), and TT
midi virus (TTMDV), discovered in 2000 and 2007 re-
spectively [6,7]. The Anelloviridae family contains 11 gen-
era and TTMV belongs to the genus Betatorquevirus,
where the TTV and TTMDV are in Alphatorquevirus and
Gammatorquevirus genera respectively [4,5]. All these* Correspondence: c.m.vanderhoek@amc.uva.nl
1Laboratory of Experimental Virology, Department of Medical Microbiology,
Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical
Center, University of Amsterdam, Amsterdam, The Netherlands
Full list of author information is available at the end of the article
© 2013 Jazaeri Farsani et al.; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumviruses have similar genome structure but different gen-
ome sizes: 3.7-3.8 kb for TTV, 3.2 kb for TTMDV and 2.8-
2.9 for TTMV [6-9].
Using alternative splicing, TTV generates three mRNA
species and produces at least six proteins by alternative
translation initiation [10]. TTV ORF1 is the largest ORF
and encodes a capsid protein, which has an arginine-rich N
terminus that is suggested to have DNA binding activity
and to function in packaging of the viral DNA [3,11,12].
The noncoding region, highly conserved among TTVs [13],
has a very high GC content and is around 170 bp in size.
TTVs are widely spread in the whole human population
and most people carry a TTV or TTMV infection but the
association of TTV with disease is unclear [14-16]. More-
over, the immunological properties, the possible pathogenic
role and other aspects of TTVs are still poorly understood.
Persistent infection and co-infection with several genotypes
are common [17-19], and some investigations suggest that
TTVs are associated with hepatitis, gastritis, cancer, and
acute respiratory diseases (see below), but no clear evidenceCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Genomic organization of the new TTMV genotype.
Arrows represent ORFs, and the box indicates the GC-rich region.
Putative proteins sizes for each ORF are given in amino acids: The
ORF1 encodes a 662 amino acid long putative capsid protein, ORF2
and ORF3 a 94 and 126 amino acid putative protein, respectively.





































Figure 2 TTMV phylogeny derived from ORF1 amino acid
sequences. ORF1 amino acid sequences (662 amino acids) of known
TTMVs were aligned with TTMV-13 and phylogenetically analyzed.
Numbers at nodes indicate bootstrap support (1000 replicates). The scale
bar is a measure of the proportion of divergence. LogL =−20869.57.
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fied in tumors of the gastrointestinal tract and myelomas
[20]. Furthermore, several studies have mentioned the pos-
sible association of TTV with respiratory disease, asthma
and its role in prognosis of idiopathic pulmonary fibrosis
[21-25], while others suggested a possible association of
TTV with aplastic anemia, childhood leukemia, and lymph-
omas [26-28]. It is also possible that the viral load, co-
infections with multiple types or other agents, the immune
status of the host, differences in genomic sequence or more
of these factors at the same time have an influence on the
pathogenicity [29]. TTVs reveal a remarkable heterogen-
eity and multiple genotypes have already been described
[13]. It is possible that only some genotypes of TTV have
a capacity to cause disease or are characterized by a higher
pathogenicity than others [30]. Therefore, to have a com-
prehensive view on TTVs and consider their possible roles
in human infections, identification of all genotypes is
needed, as it represents the first step towards understand-
ing the epidemiology, the immunology, the pathogenesis
and other aspects of this virus family. In this study we de-
scribe a new genotype of TTMV identified in serum of
two HIV-1 positive patients, which we tentatively named
TTMV-13.
Results
In search for novel viruses which are potentially transmit-
ted via blood-blood contact, we screened serum of 55
HIV-1 positive injecting drug users from the Amsterdam
Cohort Studies via VIDISCA-454, an unbiased virus dis-
covery method that can detect both RNA and DNA vi-
ruses [31]. From the total of 285,400 obtained reads a
novel torque teno mini virus (TTMV) was identified and
its full genome was obtained via genome walking with tar-
get specific primers and nested inverse PCR.
Genome organization and phylogenetic analysis
The genome of the virus carries the characteristic fea-
tures of TTMVs (see Figure 1). The ORF1, the largest
open reading frame, encodes a 662 amino acid long pu-
tative capsid protein which presents four potential glyco-
sylation sites; no signal peptides were identified. As in
other TTVs, the capsid protein is arginine rich in its N
terminus and presents two conserved motives, motif 3
(YXXK) and motif 4 with 2 changes (GXXXXGNP in-
stead of GXXXXGKS), which have been identified previ-
ously in ORF1 of other TTVs [3,32]. The second ORF
encodes a putative Rep protein of 94 amino acids. ORF
2 of TTV and TTMV can contain some conserved com-
mon motifs [6,33]. The WX7HX3CXCX5H motif was
found in the ORF2 of the new TTMV described here
(CX7HX3CXCX5H) at the AA positions 15–34. A palin-
dromic sequence (GGGGGCTCCGCCCCC) is repeated
two times in the 3′end of genome and a GC-rich regionis also present in the non-coding part, as similarly re-
ported for TTMV, TTV and TTMDV [2,6].
A full length genome sequence was obtained from a sec-
ond patient (D11, see below). In general the two viruses
were very similar, with the same genome composition and
overall less than 1% difference in nt identity. The variation
was mainly in the ORF1 gene (1.1%), and the ORF2 genes
were 100% identical at nucleotide level.
Phylogenetic analysis shows that TTMV-13 does not
cluster with any of the known TTMVs (Figure 2). The novel
TTMV-13 has only 38.6% amino acid identity in ORF1 to
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Figure 2, diversification is large among TTMVs.
Clinical characteristics of infected patients and viral
prevalence among the studied cohort
The patient (D50) in which the virus was originally de-
tected was male, known HIV-1 positive since entry
of the Amsterdam Cohort Studies, and followed for
43 months until death (April 1989 - January 1993). The
patient was diagnosed with AIDS, 6 months after entering
the study (pneumocystis carinii pneumonia). At the same
time (6 months after study entry) zidovudine treatment was
started. Seven months before death the patient developed a
pneumococcal pneumonia, which was treated with sulfa-
methoxazole. The sample in which the TTMV was detected
was collected 16 months since study entry (June 1991). Be-
sides the novel TTMV, the VIDISCA-454 sequence reads
also showed that the patient was coinfected with HCV
(2,5% of the sequences) and several known members of the
Anelloviridae (2,1% of the reads). Furthermore, HIV-1 was
detected as expected (0,1% of the sequences).
To investigate whether the virus was circulating among
injecting drug users, a diagnostic-TTMV13-specific-real
time PCR was developed and 548 samples from 385 HIV-
1 positive injecting drug users, randomly chosen from the
Amsterdam Cohort Studies, were screened for presence of
the virus (collection dates 1985–1995). One additional pa-
tient carrying the virus was identified. This patient (D11)
was male, HIV-1 and HCV positive since entry of the
Amsterdam Cohort Studies, and followed from June 1993
until death June 1998. AIDS was diagnosed 22 months
since study entry (candida oesophagitis). At that time the
patient had been treated with zidovudine for 20 months,
which was supplemented with lamivudine after AIDS
diagnosis. The patient developed a pneumococcal pneu-
monia and died due to a pneumococcal sepsis 5 years after
study entry. The TTMV positive sample was collected
9 months since study entry (January 1994).
To investigate whether the TTMV infection was chronic,
sequential serum samples form both patients collected over
the study period were screened for viral DNA. In both pa-
tients the virus was detectable over a prolonged period in
time. Patient D50 was TTMV-13 positive during the first
26 months of follow up, whereas patient D11 became posi-
tive 7 months after study entry and cleared the virus at
month 27 (see Figure 3A and B). In general, viral loads for
Patient D11 were low (103 -104 copies/ml) except one peak
in 1994.
In search for a disease association, all collected clinical
and laboratory data were examined for specific factors
which were in common for both TTMV-13 positive pa-
tients. Both patients have suffered a pneumococcal pneu-
monia during follow up and both patients had extremely
low B-cells counts (both B-cells < 0.05 cells/mm3 blood,see Figure 3). It is possible that TTMV-13 infection is
causing the low B-cell counts, suggesting that the virus is
replicating in B-cells. To this end B-cells from the first pa-
tient were isolated and co-cultured with primary B-cells
from a healthy donor or B cell lines (Ramos), but signs of
replication – cytopathic effect, cell death or increase in
viral DNA in supernatant or cells - was not observed (data
not shown). A second possibility is that TTMV-13 is
present at detectable levels in patients in which the im-
mune pressure is seriously hampered due to low B-cell
counts. To explore this hypothesis, we selected from the
Amsterdam Cohort studies all subjects with consistently
low B-cell counts (B-cells <0.05 cells/mm3): a total of 26
HIV-1 positive injecting drug users and 19 HIV-1 positive
men having sex with men were examined for the presence
of the virus but none of the serum or EDTA-plasma sam-
ples resulted positive. Attempts to express the viral capsid
protein or parts of this protein in a prokaryotic protein ex-
pression system (pET100/TOPO in E.coli Rosetta 2 (Nova-
gen)) were unsuccessful, therefore no serological test
could be developed.
Discussion
In this study we report a new genotype of torque teno
mini virus which was discovered in serum of two HIV-1
infected patients. According to the latest ICTV update
[4,5], there are 12 species of TTMV identified untill now;
therefore we tentatively named the new virus TTMV-13.
Based on phylogenetic inference of the amino acids se-
quences of ORF1, TTMV-13 is beyond doubt different
from the known ones. It is known that there is a large vari-
ability among the TTVs, not only between types, but also
within a certain type [34]. In that light it is surprising that
the nucleotide identity between the two viruses sequenced
from the two patients was remarkably high: >99% nucleo-
tide identity. It could be that the two patients, who both
shared needles, infected each other, however patient D50
deceased in 1992, whereas the first sample positive for the
virus of patient D11 was obtained in 1994, therefore direct
transmission of the virus is not likely.
Infection by the virus was chronic in both patients, al-
though in both cases the virus became undetectable after
a few years. It could be that the TTMV was poorly cleared
by the host because of the hampered immunity, in fact
both patients had low CD4 cell counts (below average)
and were at the end stage of HIV-1 disease. It is known
that HIV-1 affects humoral immunity through changes in
the B-cell compartment [35], loss of memory B-cell sub-
sets and B-cell exhaustion [36]. TTVs can replicate in
PBMC and the viral DNA has been detected in NK cells,
granulocytes cells, monocytes, B lymphocytes and T lym-
phocytes [23,37]. In one study TTV DNA was detected in
the lymph nodes of patients with B-cell lymphomas and
Hodgkin’s disease [27] and the role of TTV in lymphomas
AB D11



































































Figure 3 Follow up data of patient D50 (A) and D11 (B) infected by the new genotype of TTMV. On the X-axis the time of follow up in
the Amsterdam Cohort Studies is shown, the cell counts (cells/mm3) on the left Y-axis and the concentration of the TTMV-13 virus in copies per
ml on the right Y-axis. TTMV-13 virus loads below the detection limit (100 copies/ml serum) are indicated as 100 copies/ml.
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possible that the low B-cell count is caused by the infec-
tion with TTMV, or a combination of an HIV-1 and
TTMV infection. In one patient (patient D11, Figure 3)
the low B-cell count preceded the infection with the novel
TTMV-13, therefore it is not likely that the TTMV-13 was
the sole cause of the low B-cell counts. Involvement of the
novel TTMV-13 in pneumonia can also be considered,
since it has been shown that TTMV can be detected in
children hospitalized for severe pneumonia with para-
pneumonic empyema (PPE) and Galmes et al. suggested a
possible role of TTMV in the pathogenesis of pneumonia
[38]. TTVs are able to aggravate bacterial and viral infec-
tions by their ability to replicate in proliferating lympho-
cytes and impair the antimicrobial defenses of the host
[39]. This mechanism is known for other small circularviruses such as chicken anaemia virus [40]. In some stud-
ies, association of TTV with aggravated course of multi-
factorial diseases such as asthma and arthritis has been
suggested [24,39,41]. Furthermore, an association of TTV
load with severity of acute respiratory diseases (ARD) in
patients positive for community-acquired respiratory vi-
ruses (adenovirus group, cytomegalovirus, influenza A and
B viruses, parainfluenza virus types 1 to 3, and RSV) has
been described previously [22]. Both TTMV-13 positive
patients had a pneumococcal pneumonia: one patient had
pneumonia during the period in which TTMV-13 was de-
tectable in blood and the second patient developed pneu-
monia when TTMV-13 was no longer detectable in blood
(patient D11). It still could be that the virus had continued
replicating at a lower level in patient D11, with viral loads
below the detection limits of our diagnostic assay. In
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stantly low, with exception of a viral load peak in 1994 for
what regards patient D11, which might have been the time
of primary infection. Later time-points were negative or
close to the detection level of our diagnostic PCR assay
thus prolonged and continued infection with low levels of
virus in blood could have been missed.
Conclusion
With the discovery of the novel TTMV-13 we are one
step further with revealing the full spectrum of geno-
types and sequence variation among anelloviruses.Methods
Clinical samples
Serum samples of HIV-1 infected individuals were obtained
from the Amsterdam Cohort Studies on HIV infection and
AIDS [42]. The selected patients were injecting drug users
who were HIV-1 positive at entry of the Amsterdam Cohort
Studies. Samples (N = 55) for VIDISCA-454 (virus discovery
cDNA-AFLP, Amplified Fragment–Length Polymorphism
combined with Roche 454 high-throughput sequencing)
were collected at least 2 years since study entry and were se-
lected to be from patients whose CD4 counts decreased
below 0.3 cells/mm3 (characteristics are shown in Additional
file 1: Table S1). The Amsterdam Cohort Studies has been
conducted in accordance with the ethical principles set out
in the declaration of Helsinki and written informed con-
sent has been obtained. The study was approved by the
Academic Medical Center institutional medical ethics
committee.
VIDISCA-454 and full-length genome sequencing
and characterization
VIDISCA-454 was performed with 110 μl of serum/
EDTA-plasma samples as previously described [31]. Full
length sequencing of the virus was performed via genome
walking starting from fragments identified with VIDISCA-
454. After extraction of nucleic acids from the serum sam-
ples [43], DNA walking (Seegene) with target specific
primers was used together with a nested inverse PCR.
Primers used for sequencing are shown in Additional file
2: Table S2. PCR products were cloned into pCR2-TOPO
vector and sequencing was performed employing Big Dye
terminator chemistry (BigDye® Terminator v1.1 Cycle Se-
quencing Kit, Applied Biosystems). Sequences were ana-
lyzed with Codoncode Aligner software (version 3.7.1).
Open reading frames were identified via ORF finder
(http://www.ncbi.nlm.nih.gov/gorf/gorf.html). N- and O-
linked glycosylation sites and signal peptide cleavage sites
were predicted using the NetNGly 1.0, NetOGly 3.1, and
SignalP 4.0 analysis tools, from the Center for Biological
Sequence Analysis (http://www.cbs.dtu.dk/services/).Real time PCR
Nucleic acids were extracted from serum samples using the
Boom method [43]. Absolute quantification of viral DNA
(copies/ml of serum) was achieved by TTMV-13-specific
real-time qPCR kit (Platinum® Quantitative PCR SuperMix,
invitrogen) using the forward primer, 5′-ACAACACACAT
GGGAAAATGCA-3′, reverse primer, 5′-CTTTTGGTGT
GTTGCCCTGTTG-3′, and the probe, 5′-FAM-TATT
TTTAGGAAACACATTAGACAA-TAMRA-3′. Real-Time
PCR was performed on an ABI Prism 7000 Sequence De-
tection System machine. A positive control was prepared
by cloning PCR products into the pCR2-TOPO plasmid
vector according to the instructions of the manufacturer
(Invitrogen, Karlsruhe, Germany) followed by plasmid
DNA isolation with QIAprep Spin Miniprep Kit (Qiagen,
Hilden, Germany). Plasmid concentration was quantified
using Nanodrop 2000 (Thermo Scientific) and a standard
curve with 1:10 serial dilutions was prepared as reference
for DNA quantification. The detection limit for the assay
was 100 copies/ml.Phylogenetic analysis
Available complete TTMV genome sequences in Gen-
Bank database (http://www.ncbi.nlm.nih.gov/genbank/)
were used for the analysis (accession numbers are listed
in Figure 2). Redundancies were removed and the few
nucleotide ambiguities were solved via replacement by
either the consensus nucleotide at the position involved
or the corresponding nucleotide of the nearest neigh-
bor. At absence of these opportunities, a gap was intro-
duced in the translated reading frames. The amino acid
sequences of ORF1 were aligned by means of ProbCons
[44] using default parameters. Phylogenetic and mo-
lecular evolutionary analyses were conducted using
MEGA version 5.2 [45]. The WAG + Freq + G + I model
for assessing amino acid replacements during TTMV
evolution turned out to be the best fitting model
judged by BIC score (Bayesian Information Criterion,
42296.3052) and AICc value (corrected Akaike Infor-
mation Criterion, 41880.2816) and therefore used
for the following Maximum likelihood phylogenetic
analysis via Mega5 [45]. Non-uniformity of evolutionary
rates among sites has been modeled by using a discrete
Gamma distribution (+G = 2.3418) with 5 rate ca-
tegories and by assuming that a certain fraction of
sites is evolutionarily invariable (+I = 0.0280). Max-
imum Likelihood (ML) value for model selection was
logL = −20883.8854. In view of the relatively low num-
ber of taxa, all sites were used for phylogenetic analysis.
To test the robustness of the analysis, a bootstrap test
(1000 replicates) was performed and only clusters asso-
ciated with a value higher then 75% were considered
significant [46].
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Two complete genome sequences of TTMV-13 obtained
in this study have been deposited in the GenBank data-
base under accession numbers KF764701 and KF764702.
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sequencing.
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